Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Medtech
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds and APIs
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
Multimedia
Blog
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Breadcrumb
Home
Vantage
Pharmaceutical Companies
Impax Laboratories
July 18, 2017
Drug pricing spotlight shifts to generics with no rivals
September 03, 2015
UCB far from rehabilitated, despite divestment and study success
September 10, 2014
Keryx and Galenica face a tough battle to build phosphate franchises
February 27, 2013
Biotie and UCB tie the knot with pivotal trial pre-nup
January 21, 2013
More off time for Impax as FDA rejects Rytary
December 24, 2012
Midcap players ask Europe to bring it on in 2013
October 04, 2012
Same, same but different Wellbutrin could cause problems for generics companies
October 03, 2012
Event – Impax hopes for some originality with Rytary approval
July 20, 2012
Key regulatory events for the next six months in Q3 and Q4 in 2012
June 25, 2012
Shire needs pipeline focus to recover from early Adderall blow
August 10, 2010
No brainer for Endo as Penwest activists win the day
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
September 22, 2022
ESMO 2022 eBook
September 01, 2022
PD(L)anner – September 2022
Editor's Picks
July 27, 2022
Aids 2022 preview – Gilead shoots for an HIV cure
July 21, 2022
Private equity gets serious about drug development
July 18, 2022
Unpacking Royalty Pharma
July 19, 2022
No plain sailing for Novartis’s PD-1 plan
July 26, 2022
Move over Aduhelm, it’s tofersen’s turn
